Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 24Unknown 6Terminated 4Not yet recruiting 3Withdrawn 2Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Peritoneal Diseases 1

Interventions

Fluorouracil 51Oxaliplatin 49Gemcitabine 47Leucovorin 41Capecitabine 35Bevacizumab 29Irinotecan 25Cisplatin 22Radiotherapy 18Radiosurgery 18pembrolizumab 16Nivolumab 16Cetuximab 15Taxes 14Sorafenib 14Paclitaxel 13Biopsy 13Surgical Procedures, Operative 12Drug Therapy 11atezolizumab 10Radiation 10Albumin-Bound Paclitaxel 10lenvatinib 9durvalumab 9Magnetic Resonance Spectroscopy 9Folfox protocol 9Cyclophosphamide 9130-nm albumin-bound paclitaxel 9spartalizumab 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Pancreaticoduodenectomy × Gastrointestinal × Clear all
NCT02850874 2022-04-27

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Wake Forest University Health Sciences

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms, Peritoneal Diseases

NCT03718650 2021-02-08

Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡